There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Stemline Therapeutics Inc (NASDAQ: STML) and Global Blood Therapeutics (NASDAQ: GBT) with bullish sentiments.
Stemline Therapeutics Inc (NASDAQ: STML)
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Stemline Therapeutics Inc (NASDAQ: STML) today and set a price target of $38. The company’s shares closed on Friday at $17.80.
According to TipRanks.com, Selvaraju is a 3-star analyst with an average return of 2.4% and a 42.0% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
Currently, the analyst consensus on Stemline Therapeutics Inc is Strong Buy and the average price target is $34, representing a 91.0% upside.
In a report issued on June 12, Roth Capital also initiated coverage with a Buy rating on the stock with a $30 price target.
See today’s analyst top recommended stocks >>
Global Blood Therapeutics (NASDAQ: GBT)
H.C. Wainwright analyst Debjit Chattopadhyay maintained a Buy rating on Global Blood Therapeutics (NASDAQ: GBT) today and set a price target of $73. The company’s shares closed on Friday at $40.05.
According to TipRanks.com, Chattopadhyay is a 3-star analyst with an average return of 2.6% and a 47.8% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Mersana Therapeutics Inc, Voyager Therapeutics Inc, and Jounce Therapeutics Inc.
Currently, the analyst consensus on Global Blood Therapeutics is Strong Buy and the average price target is $72.13, representing an 80.1% upside.
In a report issued on June 15, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $69 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on GBT:
